Atrial Fibrillation
Atrial fibrillation is an abnormal heart rhythm which involves the two small, upper heart chambers. Heart beats in a normal heart begin after electricity generated in the atria by the sinoatrial node spreads through the heart and causes contraction of the heart muscle and pumping of blood. In AF, the regular electrical impulses of the sinoatrial node are replaced by disorganized, rapid electrical impulses which result in irregular heart beats.
Atrial fibrillation is the most common cardiac arrhythmia. The risk of developing atrial fibrillation increases with age — AF affects four percent of individuals in their 80s. An individual may spontaneously alternate between AF and a normal rhythm or may continue with AF as the dominant cardiac rhythm without reversion to the normal rhythm. This variety of disorder is sometimes associated with the secretion of adrenalin under conditions of emotional stress in this age group.
Atrial fibrillation is often asymptomatic, but may result in symptoms of palpitations, fainting, chest pain, or even heart failure. These symptoms are especially common when atrial fibrillation results in a heart rate which is either too fast or too slow. In addition, the erratic motion of the atria leads to blood stagnation which increases the risk of blood clots that may travel from the heart to the brain and other areas. Thus, AF is an important risk factor for stroke, the most feared complication of atrial fibrillation.
The symptoms of atrial fibrillation may be treated with medications which slow the heart rate. Several medications as well as electrical cardioversion may be used to convert AF to a normal heart rhythm. Surgical and catheter-based therapies may also be used to prevent atrial fibrillation in certain individuals. People with AF are often given blood thinners such as warfarin to protect them from strokes.
Atrial fibrillation is usually accompanied by symptoms related to either the rapid heart rate or embolization. Rapid and irregular heart rates may be perceived as palpitations, exercise intolerance, and occasionally produce angina and congestive symptoms of shortness of breath or edema. Sometimes the arrhythmia will be identified with the onset of a stroke or a transient ischemic attack (TIA). It is not uncommon to identify atrial fibrillation on a routine physical examination or electrocardiogram (ECG/EKG), as it may be asymptomatic in some cases.
The main goals of treatment of atrial fibrillation are to prevent temporary circulatory instability and to prevent stroke. Rate and rhythm control are principally used to achieve the former, while anticoagulation may be required to decrease the risk of the latter. The primary factors determining atrial fibrillation treatment are duration and evidence of hemodynamic instability. Cardioversion is indicated with new onset AF and with hemodynamic instability.
AF can cause disabling and annoying symptoms. Palpitations, angina, lassitude, and decreased exercise tolerance are related to rapid heart rate and inefficient cardiac output caused by AF. There are two ways to approach these symptoms: rate control and rhythm control. Rate control treatments seek to reduce the heart rate to normal, usually 60 to 100 beats per minute. Rhythm control seeks to restore the normal heart rhythm, called normal sinus rhythm. Studies suggest that rhythm control is mainly a concern in newly diagnosed AF, while rate control is more important in the chronic phase. Rate control with anticoagulation is as effective a treatment as rhythm control in long term mortality studies, the AFFIRM Trial.
AF with a persistent rapid rate can cause a form of heart failure called tachycardia induced cardiomyopathy. This can significantly increase mortality and morbidity. The early treatment of AF through either rate-control or rhythm-control can prevent this condition and thereby improve mortality and morbidity.
...More at Wikipedia
Related Links:
Atrial Fibrillation
Questions recently asked by other users
Latest Cardiovascular / Cardiology News From Medical News Today.
- Trans Fats To Be Phased Out In California As Governor Schwarzenegger Signs Bill
- Bayer's Novel Anticoagulant Rivaroxaban Recommended For EU Approval - Venous Blood Clot Prevention After Elective Hip Or Knee Replacement Surgery
- Key Mechanism Of Cellular Damage In Aging And Disease Unravelled
- National Survey Finds That 14% Of Primary Care Nurses Have Never Undertaken Any Type Of Basic Training In Cardiovascular Disease, UK
- Macrophages May Be Marker For Atherosclerosis
- Bioheart Reports Promising Results From SDF-1 Modified MyoCell(R) Therapy In Heart Failure Study
- Emergency Physicians Have Good First Instincts In Diagnosing Heart Attacks
- Exercise Could Be The Heart's Fountain Of Youth
- Duska Therapeutics Submits Phase 3 ATPace(TM) Protocol To FDA For Comment
- FluoroPharma Announces Positive Phase I Safety Results For BFPET(TM), Myocardial Perfusion Imaging (MPI) Tracer For Positron Emission Tomography (PET)
- Study Reveals Potential For NT-proBNP As A Marker To Predict Cardiovascular Risks From Anti-Inflammatory Drugs
-
cinnycinny

How does this condition aff...
